Various forms of HIF-1α protein characterize the clear cell renal cell carcinoma cell lines

被引:13
|
作者
Swiatek, Monika [1 ]
Jancewicz, Iga [1 ]
Kluebsoongnoen, Jakkapong [2 ]
Zub, Renata [1 ]
Maassen, Anna [3 ]
Kubala, Szymon [3 ]
Udomkit, Apinunt [2 ]
Siedlecki, Janusz A. [1 ]
Sarnowski, Tomasz J. [3 ]
Sarnowska, Elzbieta [1 ]
机构
[1] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Mol & Translat Oncol, Warsaw, Poland
[2] Mahidol Univ, Inst Mol Biosci, Salaya, Nakhon Pathom, Thailand
[3] Polish Acad Sci, Inst Biochem & Biophys, Warsaw, Poland
关键词
clear cell renal cell carcinoma; glycolysis; HIF-1; alpha; metabolism; SWI; SNF; HYPOXIA-INDUCIBLE FACTOR; LINDAU TUMOR-SUPPRESSOR; FACTOR; 1-ALPHA; CANCER; FACTOR-1-ALPHA; MECHANISM; SURVIVAL; COMPLEX; BINDING; ALPHA;
D O I
10.1002/iub.2281
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Renal cell carcinoma (RCC) represents around 2-3% of all malignancies diagnosed in adult patients. Most frequent (around 70-80% cases) and the most aggressive subtype is clear cell RCC (ccRCC). Mutations in VHL (von Hippel Lindau) gene, characteristic for this cancer type, lead to altered activity of the trimeric VBC (pVHL-elongin B-C) complex and consequently to HIF-1 alpha stabilization. In this study, we present results of exhaustive investigation of HIF-1 alpha alternative transcript variants abundance in A498, CAKI-1, and 786-O ccRCC cell lines. We proved the existence of truncated HIF-1 alpha protein form (HIF1A increment -6) in A498 and HIF1A gene rearrangements in 786-O cell lines. Subsequently, we found that HIF1A increment 2-6 was more stable than the full-length HIF-1 alpha. Moreover, the shorter HIF-1 alpha was insensitive for hypoxia and was overaccumulated after proteasome inhibitor treatment indicative of potential diversified roles of full-length and truncated HIF-1 alpha forms in the cell. We also showed that A498, CAKI-1, and 786-O exhibit differential expression of various regulatory genes involved in the control of metabolic processes, that is, glucose and lipid metabolism, and encoding subunits of such machineries like SWI/SNF chromatin remodeling complex. Furthermore, these cell lines exhibited differential responses to axitinib, everolimus, and sunitinib-anticancer drugs-in normoxia and hypoxia as well as various alterations in metabolism-related regulatory processes. Finally, we have shown that overexpression of truncated HIF1A increment 2-6 form may affect the protein level of endogenous full-length HIF-1 alpha protein. Thus, our study proves an important role of HIF-1 alpha in the ccRCC development.
引用
收藏
页码:1220 / 1232
页数:13
相关论文
共 50 条
  • [1] Survival in Patients with Clear Cell Renal Cell Carcinoma Is Predicted by HIF-1α Expression
    Minardi, Daniele
    Lucarini, Guendalina
    Santoni, Matteo
    Mazzucchelli, Roberta
    Burattini, Luciano
    Conti, Alessandro
    Principi, Emanele
    Bianconi, Maristella
    Scartozzi, Mario
    Milanese, Giulio
    Di Primio, Roberto
    Montironi, Rodolfo
    Cascinu, Stefano
    Muzzonigro, Giovanni
    ANTICANCER RESEARCH, 2015, 35 (01) : 433 - 438
  • [2] HIF-1 mediates the Warburg effect in clear cell renal carcinoma
    Semenza, Gregg L.
    JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, 2007, 39 (03) : 231 - 234
  • [3] HIF-1 mediates the Warburg effect in clear cell renal carcinoma
    Gregg L. Semenza
    Journal of Bioenergetics and Biomembranes, 2007, 39 : 231 - 234
  • [4] Analysis of HIF-1α expression and genetic polymorphisms in human clear cell renal cell carcinoma
    Vargova, Daniela
    Kolkova, Zuzana
    Dargaj, Jan
    Bris, Lukas
    Luptak, Jan
    Dankova, Zuzana
    Franova, Sona
    Svihra, Jan
    Slavik, Pavol
    Sutovska, Martina
    PATHOLOGY & ONCOLOGY RESEARCH, 2024, 29
  • [5] Strict regulation of CAIXG250/MN by HIF-1α in clear cell renal cell carcinoma
    Grabmaier, K
    de Weijert, MCA
    Verhaegh, GW
    Schalken, JA
    Oosterwijk, E
    ONCOGENE, 2004, 23 (33) : 5624 - 5631
  • [6] Strict regulation of CAIXG250/MN by HIF-1α in clear cell renal cell carcinoma
    Karin Grabmaier
    Mirjam CA de Weijert
    Gerald W Verhaegh
    Jack A Schalken
    Egbert Oosterwijk
    Oncogene, 2004, 23 : 5624 - 5631
  • [7] The RNA-binding protein QKI suppresses tumorigenesis of clear cell renal cell carcinoma by regulating the expression of HIF-1α
    Shi, Fei
    Wei, Di
    Zhu, Zheng
    Yan, Fei
    Wang, Fuli
    Zhang, Keke
    Li, Xi'an
    Zheng, Yu
    Yuan, Jiarui
    Lu, Zifan
    Yuan, Jianlin
    JOURNAL OF CANCER, 2020, 11 (06): : 1359 - 1370
  • [8] HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice
    Rouven Hoefflin
    Sabine Harlander
    Silvia Schäfer
    Patrick Metzger
    Fengshen Kuo
    Désirée Schönenberger
    Mojca Adlesic
    Asin Peighambari
    Philipp Seidel
    Chia-yi Chen
    Miguel Consenza-Contreras
    Andreas Jud
    Bernd Lahrmann
    Niels Grabe
    Danijela Heide
    Franziska M. Uhl
    Timothy A. Chan
    Justus Duyster
    Robert Zeiser
    Christoph Schell
    Mathias Heikenwalder
    Oliver Schilling
    A. Ari Hakimi
    Melanie Boerries
    Ian J. Frew
    Nature Communications, 11
  • [9] HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice
    Hoefflin, Rouven
    Harlander, Sabine
    Schaefer, Silvia
    Metzger, Patrick
    Kuo, Fengshen
    Schoenenberger, Desiree
    Adlesic, Mojca
    Peighambari, Asin
    Seidel, Philipp
    Chen, Chia-yi
    Consenza-Contreras, Miguel
    Jud, Andreas
    Lahrmann, Bernd
    Grabe, Niels
    Heide, Danijela
    Uhl, Franziska M.
    Chan, Timothy A.
    Duyster, Justus
    Zeiser, Robert
    Schell, Christoph
    Heikenwalder, Mathias
    Schilling, Oliver
    Hakimi, A. Ari
    Boerries, Melanie
    Frew, Ian J.
    NATURE COMMUNICATIONS, 2020, 11 (01)
  • [10] VHL and HIF-1α: gene variations and prognosis in early-stage clear cell renal cell carcinoma
    Lessi, Francesca
    Mazzanti, Chiara Maria
    Tomei, Sara
    Di Cristofano, Claudio
    Minervini, Andrea
    Menicagli, Michele
    Apollo, Alessandro
    Masieri, Lorenzo
    Collecchi, Paola
    Minervini, Riccardo
    Carini, Marco
    Bevilacqua, Generoso
    MEDICAL ONCOLOGY, 2014, 31 (03)